DENTSPLY SIRONA Inc. (NASDAQ:XRAY)‘s stock had its “overweight” rating reiterated by investment analysts at Morgan Stanley in a research report issued on Friday. They currently have a $69.00 price target on the medical instruments supplier’s stock, up from their prior price target of $67.00. Morgan Stanley’s target price points to a potential upside of 17.93% from the company’s previous close.

Several other equities analysts have also issued reports on the company. Cleveland Research lowered DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a research note on Thursday. HC Wainwright reissued a “buy” rating and set a $68.00 target price on shares of DENTSPLY SIRONA in a research note on Tuesday. Jefferies Group LLC decreased their target price on DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating on the stock in a research note on Wednesday, August 23rd. BidaskClub lowered DENTSPLY SIRONA from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 16th. Finally, Zacks Investment Research lowered DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $65.89.

DENTSPLY SIRONA (NASDAQ XRAY) traded down 0.80% during mid-day trading on Friday, hitting $58.51. The stock had a trading volume of 3,205,156 shares. The firm’s 50-day moving average price is $57.06 and its 200 day moving average price is $61.28. The company’s market cap is $13.43 billion. DENTSPLY SIRONA has a one year low of $52.54 and a one year high of $65.68.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.65. DENTSPLY SIRONA had a positive return on equity of 7.24% and a negative net margin of 20.57%. The firm had revenue of $992.70 million for the quarter, compared to analyst estimates of $1 billion. During the same quarter in the prior year, the company earned $0.76 EPS. DENTSPLY SIRONA’s revenue was down 2.9% on a year-over-year basis. On average, equities research analysts anticipate that DENTSPLY SIRONA will post $2.68 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/06/dentsply-sirona-inc-xray-price-target-raised-to-69-00-at-morgan-stanley.html.

A number of hedge funds have recently bought and sold shares of XRAY. UBS Asset Management Americas Inc. raised its position in DENTSPLY SIRONA by 4.1% in the 1st quarter. UBS Asset Management Americas Inc. now owns 1,024,996 shares of the medical instruments supplier’s stock valued at $64,001,000 after purchasing an additional 40,816 shares in the last quarter. Nordea Investment Management AB raised its position in DENTSPLY SIRONA by 1.4% in the 1st quarter. Nordea Investment Management AB now owns 10,160 shares of the medical instruments supplier’s stock valued at $634,000 after purchasing an additional 137 shares in the last quarter. Rafferty Asset Management LLC raised its position in DENTSPLY SIRONA by 8.5% in the 1st quarter. Rafferty Asset Management LLC now owns 18,176 shares of the medical instruments supplier’s stock valued at $1,135,000 after purchasing an additional 1,417 shares in the last quarter. Veritas Asset Management LLP raised its position in DENTSPLY SIRONA by 5.0% in the 1st quarter. Veritas Asset Management LLP now owns 6,043,539 shares of the medical instruments supplier’s stock valued at $377,359,000 after purchasing an additional 287,800 shares in the last quarter. Finally, Gofen & Glossberg LLC IL acquired a new stake in DENTSPLY SIRONA in the 1st quarter valued at about $346,000. 93.87% of the stock is currently owned by institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.